Investor Presentaiton slide image

Investor Presentaiton

ENHERTU Revenue 0000 FY2022 Q1 Results YOY FY2022 Forecast <Reference> YOY Total Consideration Product Sales 31.3 18.4 128.4 63.0 Japan US Europe ASCA Upfront payment Regulatory milestone payment US HER2+ Breast Cancer 3L 2.4 0.3 16.0 6.4 20.0 10.5 83.1 37.7 6.7 5.5 23.0 14.0 2.2 2.2 6.3 4.9 * 1 * 1 2.5 - 9.8 149.0 * 1 *1 3.4 2.8 20.6 18.3 100.3 0.2 0.9 13.7 EU HER2+ Breast Cancer 3L 0.1 0.5 7.9 US HER2+ Gastric Cancer 2L + 3L 0.2 0.8 12.1 US HER2+ Breast Cancer 2L 2.8 2.8 3.4 3.4 13.1 EU HER2+ Breast Cancer 2L 2.6 2.6 9.8 *2 22 US HER2-low Breast Cancer (post-chemo) 6.9 6.9 26.0 *2 EU HER2+ Gastric Cancer 2L 1.2 1.2 4.6 *2 US HER2+ or HER2 Mutant NSCLC 2L 4.3 4.3 13.1 *2 Quid related payment 0.3 *1 0.3 1.1 *1 -2.3 17.2 Total 37.4 21.4 159.9 79.1 266.5 *1 Revenue recognized in each period (Bn JPY) *2 Revenue based on the assumption that milestone will be achieved in FY2022; Expected consideration converted with forex rate of 130 JPY to 1 USD Daiichi-Sankyo 11
View entire presentation